[go: up one dir, main page]

MA67365B1 - Dérivés de benzisoxazole sulfonamide - Google Patents

Dérivés de benzisoxazole sulfonamide

Info

Publication number
MA67365B1
MA67365B1 MA67365A MA67365A MA67365B1 MA 67365 B1 MA67365 B1 MA 67365B1 MA 67365 A MA67365 A MA 67365A MA 67365 A MA67365 A MA 67365A MA 67365 B1 MA67365 B1 MA 67365B1
Authority
MA
Morocco
Prior art keywords
sup
compounds
derivatives
benzisoxazole
sulfonaminate
Prior art date
Application number
MA67365A
Other languages
English (en)
Inventor
Robert Arnold Kumpf
Pei-Pei Kung
Scott Channing Sutton
Samantha Elizabeth GREASLEY
Robert Louis Hoffman
Paul Francis Richardson
Ylva Elisabet Bergman BOZIKIS
Oleg Brodsky
Michelle Ang CAMERINO
Paul Anthony Stupple
Original Assignee
Pfizer Inc.
Ctxt Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc., Ctxt Pty Ltd filed Critical Pfizer Inc.
Publication of MA67365B1 publication Critical patent/MA67365B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La présente invention concerne des composés de formule (I) ou des sels pharmaceutiquement acceptables de ceux-ci, dans lesquels le cycle A, R<sup>1</sup>-R<sup>8</sup> et n sont définis ici. Les nouveaux dérivés de sulfonamide de benzisoxazole sont utiles dans le traitement de la croissance cellulaire anormale, telle que le cancer, chez les patients. Des modes de réalisation supplémentaires concernent des compositions pharmaceutiques contenant les composés et des procédés d'utilisation des composés et des compositions dans le traitement de la croissance cellulaire anormale chez les patients.
MA67365A 2019-06-18 2020-06-16 Dérivés de benzisoxazole sulfonamide MA67365B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962863199P 2019-06-18 2019-06-18
US201962953223P 2019-12-24 2019-12-24
US202063025278P 2020-05-15 2020-05-15
EP23203023.9A EP4299135B1 (fr) 2019-06-18 2020-06-16 Dérivés de benzisoxazole sulfonamide

Publications (1)

Publication Number Publication Date
MA67365B1 true MA67365B1 (fr) 2025-10-31

Family

ID=71738189

Family Applications (1)

Application Number Title Priority Date Filing Date
MA67365A MA67365B1 (fr) 2019-06-18 2020-06-16 Dérivés de benzisoxazole sulfonamide

Country Status (33)

Country Link
US (2) US11492346B2 (fr)
EP (2) EP3986890B9 (fr)
JP (2) JP7352662B2 (fr)
KR (1) KR102823056B1 (fr)
CN (1) CN114364672B (fr)
AU (2) AU2020296361A1 (fr)
BR (1) BR112021025528A2 (fr)
CA (1) CA3143666C (fr)
CL (1) CL2021003372A1 (fr)
CO (1) CO2021017504A2 (fr)
CR (1) CR20210627A (fr)
DK (2) DK3986890T3 (fr)
EC (1) ECSP21091615A (fr)
ES (2) ES3043899T3 (fr)
FI (2) FI4299135T3 (fr)
HR (2) HRP20251225T1 (fr)
HU (1) HUE064683T2 (fr)
IL (1) IL288802B2 (fr)
LT (2) LT4299135T (fr)
MA (1) MA67365B1 (fr)
MD (2) MD4299135T2 (fr)
MX (1) MX2021016085A (fr)
MY (1) MY210207A (fr)
PE (1) PE20220808A1 (fr)
PH (1) PH12021553107A1 (fr)
PL (2) PL3986890T3 (fr)
PT (2) PT4299135T (fr)
RS (2) RS64931B9 (fr)
SI (2) SI4299135T1 (fr)
TW (1) TWI787620B (fr)
UA (1) UA129891C2 (fr)
UY (1) UY38752A (fr)
WO (1) WO2020254946A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201810092D0 (en) * 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
AU2020282759A1 (en) 2019-05-31 2021-12-23 Ikena Oncology, Inc. TEAD inhibitors and uses thereof
RS64931B9 (sr) 2019-06-18 2025-06-30 Pfizer Derivati benzizoxazol sulfonamida
AU2020295006B2 (en) * 2019-06-19 2023-11-09 Ctxt Pty Ltd Cycloalkyl and heterocycloalkyl benzisoxazole sulfonamide derivatives
PT4181920T (pt) * 2020-07-15 2025-11-04 Ctxt Pty Ltd Inibidor de kat6 e combinações para o tratamento do cancro da mama
US20220024919A1 (en) * 2020-07-15 2022-01-27 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2022187688A1 (fr) * 2021-03-05 2022-09-09 Umbra Therapeutics Inc. Composés de liaison de kras covalents à des fins thérapeutiques
WO2022187693A1 (fr) * 2021-03-05 2022-09-09 Umbra Therapeutics Inc. Composés de liaison à cdk2 covalents utilisés à des fins thérapeutiques
EP4341259A4 (fr) * 2021-05-21 2025-05-28 Aurigene Oncology Limited Composés isoxazolyles fusionnés utilisés en tant qu'inhibiteurs de kat6a
CN118382622A (zh) * 2021-07-05 2024-07-23 杭州英创医药科技有限公司 作为kat6抑制剂的化合物
JP2024529068A (ja) 2021-08-10 2024-08-01 江蘇恒瑞医薬股▲ふん▼有限公司 スルファミド誘導体、その調製方法及びその医薬的使用
TW202334163A (zh) * 2021-11-16 2023-09-01 香港商英矽智能科技知識產權有限公司 離胺酸乙醯基轉移酶6a (kat6a)抑制劑及其用途
US20250059204A1 (en) * 2021-12-13 2025-02-20 Aurigene Oncology Limited Fused benzoisoxazolyl compounds as kat6a inhibitors
CN116621859A (zh) * 2022-02-18 2023-08-22 山东轩竹医药科技有限公司 三并环类kat6抑制剂
JP2025511122A (ja) * 2022-03-28 2025-04-15 アイソステリックス， インコーポレイテッド リジンアセチルトランスフェラーゼのｍｙｓｔファミリーの阻害剤
AU2023295547A1 (en) * 2022-06-16 2025-01-09 Prelude Therapeutics Incorporated Kat6 targeting compounds with ubiquitin ligase binding moiety
CN119604288A (zh) 2022-07-29 2025-03-11 辉瑞大药厂 用于治疗癌症的包含kat6抑制剂的给药方案
WO2024131772A1 (fr) * 2022-12-20 2024-06-27 杭州中美华东制药有限公司 Composé contenant de l'oxime ayant un effet inhibiteur de sting, composition pharmaceutique de celui-ci et son utilisation
WO2024165035A1 (fr) 2023-02-10 2024-08-15 江苏恒瑞医药股份有限公司 Forme cristalline d'un dérivé de sulfonamide et son procédé de préparation
CN120917003A (zh) 2023-03-16 2025-11-07 奥列马制药公司 酰基磺酰胺kat6a抑制剂
WO2024199254A1 (fr) * 2023-03-27 2024-10-03 北京康辰药业股份有限公司 Composé sulfonamide, composition pharmaceutique de celui-ci et utilisation associée
CN120981721A (zh) 2023-03-30 2025-11-18 辉瑞大药厂 Kat6a作为用kat6a抑制剂治疗的预测性生物标志物和相关治疗方法
TW202446378A (zh) * 2023-04-19 2024-12-01 香港商英矽智能科技知識產權有限公司 離胺酸乙醯基轉移酶6a(kat6a)抑制劑、其組合及其用途
AU2024262206A1 (en) * 2023-04-25 2025-12-04 Insilico Medicine Ip Limited Crystalline lysine acetyltransferase 6a (kat6a) inhibitor and uses thereof
CN121358728A (zh) * 2023-07-04 2026-01-16 上海齐鲁制药研究中心有限公司 Kat6抑制剂
WO2025036382A1 (fr) * 2023-08-14 2025-02-20 上海复宏汉霖生物医药有限公司 Composé sulfonamide, son procédé de préparation et son utilisation
US20250122182A1 (en) * 2023-09-27 2025-04-17 Isosterix, Inc. MYST Inhibitors
WO2025098417A1 (fr) * 2023-11-08 2025-05-15 再和医药科技（苏州）有限公司 Composé sulfonamide et son utilisation
WO2025141469A1 (fr) 2023-12-26 2025-07-03 Pfizer Inc. Forme cristalline de 2-méthoxy-n-4-méthoxy-6-[(1h-pyrazol-1-yl)méthyl]-1,2-benzoxazol-3-yl}benzène-1-sulfonamide
WO2026003716A1 (fr) 2024-06-27 2026-01-02 Pfizer Inc. Procédé de préparation de n-(6-((1h-pyrazol-1-yl) méthyl)-4-méthoxybenzo[d]isoxazol-3-yl)-2-méthoxybenzènesulfonamide

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3064003A (en) 1962-11-13 Carboxylic acid derivatives of sub-
US2358031A (en) 1944-09-12 Substituted thiadiazoles
US2525321A (en) 1949-01-07 1950-10-10 American Cyanamid Co Hydroxybenzenesulfonamidoisoxazoles and preparation of same
GB689281A (en) 1950-02-18 1953-03-25 Lunbeck Corp Improvements in or relating to the production of sulphanilamido-thiadiazoles
DE1102745B (de) 1959-06-06 1961-03-23 Boehringer & Soehne Gmbh Verfahren zur Herstellung von 5-Sulfanilamidoisoxazolen
BE617370A (fr) 1961-05-09 1962-11-08 Ciba Geigy Procédé de préparation du 2,5-di-[benzoxazolyl-(2')]-thiofène
US3332942A (en) 1962-11-02 1967-07-25 White Lab Inc Substituted thiadiazoles
JPS498255B1 (fr) 1970-10-08 1974-02-25
US3951967A (en) 1972-03-20 1976-04-20 Merck & Co., Inc. 7-Mercapto(or thio)-benzothiadiazine products
US3960854A (en) 1972-03-20 1976-06-01 Merck & Co., Inc. 7-Mercapto(or thio)-benzothiadiazine products
DE2617809C2 (de) 1976-04-23 1984-09-20 Basf Ag, 6700 Ludwigshafen Verfahren zur Stabilisierung von Chromdioxid-Magnetpigmenten und seine Verwendung
JPS6042794B2 (ja) 1977-09-27 1985-09-25 三共株式会社 イソオキサゾリウム塩，およびその製造方法
US4251664A (en) 1978-05-24 1981-02-17 Henkel Corporation Sulfonamidothiadiazoles, metal complexes thereof, and solutions containing such compounds for use in extraction of metal values
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
JPS603685B2 (ja) 1980-04-15 1985-01-30 日本コロムビア株式会社 絵入りレコ−ド盤の製造方法
GB8427618D0 (en) 1984-11-01 1984-12-05 Shell Int Research Anticoccidial compositions
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
JPS63238006A (ja) 1987-03-26 1988-10-04 Shionogi & Co Ltd イモチ防除剤
US5591761A (en) 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
FI93954C (fi) 1988-11-29 1995-06-26 Warner Lambert Co Menetelmä lääkeaineina käyttökelpoisten 3,5-di-tert-butyyli-4-hydroksifenyylisubstituoitujen 1,2,4- ja 1,3,4-tiadiatsolien sekä oksadiatsolien ja triatsolien valmistamiseksi
JPH03258771A (ja) 1990-03-09 1991-11-19 Tosoh Corp スルホンアミド誘導体、その製法及びそれを有効成分として含有する除草剤
JP2902834B2 (ja) 1991-10-09 1999-06-07 本田技研工業株式会社 自己伸縮型マウント
TW224462B (fr) 1992-02-24 1994-06-01 Squibb & Sons Inc
FR2690160A1 (fr) 1992-04-15 1993-10-22 Rhone Poulenc Rorer Sa Application de dérivés d'acide 2H-1,2,4-benzothiadiazine-1,1-dioxyde-3-carboxylique à la préparation de médicaments, les produits nouveaux, leur préparation et les médicaments les contenant.
NZ247440A (en) 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
EP0626174A3 (fr) 1993-04-21 1996-01-03 Takeda Chemical Industries Ltd Procédé et composition de prophylaxie et/ou traitement de la hypofonction d'organes.
JP3901229B2 (ja) 1994-05-13 2007-04-04 Ｎｔｎ株式会社 耐熱・潤滑性樹脂組成物
EA007107B1 (ru) 1995-04-04 2006-06-30 Инсизив Фармасьютикэлз Инк. Тиенил- и дифенилсульфонамиды и их производные, модулирующие активность эндотелина
US5804585A (en) 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
WO1998021186A1 (fr) 1996-11-13 1998-05-22 Cephalon, Inc. Inhibiteurs benzothiazo, ou contenant des groupes heterocycliques apparentes, de la cysteine ou des proteases serines
TR200101905T2 (tr) 1997-04-28 2002-06-21 Texas Biotechnology Corporation Endotelin ile ilgili hastalıkların tedavisinde kullanılan sülfanoamidler.
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
BR0014078A (pt) 1999-09-17 2002-12-31 Millennium Pharm Inc Inibidores de fator xa
AU2456701A (en) 1999-12-31 2001-07-16 Texas Biotechnology Corporation Pharmaceutical and veterinary uses of endothelin antagonists
US6376515B2 (en) 2000-02-29 2002-04-23 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor Xa
GB0127344D0 (en) 2001-11-14 2002-01-02 Cancer Res Ventures Ltd Assay method
AU2002353717B2 (en) 2001-11-22 2006-08-03 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
JP2003292485A (ja) 2002-04-01 2003-10-15 Yamanouchi Pharmaceut Co Ltd スルホンアミド誘導体
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
WO2004103980A1 (fr) 2003-05-21 2004-12-02 Biovitrum Ab Inhibiteurs de 11-beta-hydroxy steroide deshydrogenase de type i
WO2004113310A1 (fr) 2003-06-25 2004-12-29 Biovitrum Ab Utilisation d'un inhibiteur de compose de type 1 11-b-hydroxysteroide deshydrogenase type 1 destine a faciliter la cicatrisation d'une plaie
AU2004259755A1 (en) 2003-07-22 2005-02-03 Janssen Pharmaceutica, N.V. Quinolinone derivatives as inhibitors of c-fms kinase
US7615563B2 (en) 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
WO2005013914A2 (fr) 2003-08-08 2005-02-17 Vertex Pharmaceuticals Incorporated Compositions utilisees comme inhibiteurs de canaux sodium voltage dependants
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
WO2005049593A2 (fr) * 2003-11-13 2005-06-02 Abbott Laboratories Promoteurs de l'apoptose contenant n-acylsulfonamide
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
US7642260B2 (en) 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
SG156637A1 (en) 2004-10-12 2009-11-26 Decode Genetics Ehf Aryl sulfonamide peri-substituted bicyclics for occlusive artery disease
BRPI0610258A2 (pt) 2005-04-26 2012-09-25 Hypnion Inc composto ou um sal farmaceuticamente eficaz do mesmo, composição farmacêutica, e, uso de um composto
DK1877390T3 (da) 2005-04-26 2010-05-31 Hypnion Inc Benzisoxazol-piperazin-forbindelser og fremgangsmåder til anvendelse deraf
ZA200710332B (en) 2005-05-16 2009-03-25 Vertex Pharma Bicyclic derivatives as modulators of ion channels
DE102005038947A1 (de) 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
RU2008113209A (ru) 2005-10-06 2009-10-10 Санофи-Авентис (Fr) Бициклические {1, 3, 4}тиадиазол-2-иламиды арилсульфоновой кислоты, способы их получения и их использование в качестве фармацевтических средств
BRPI0616800A2 (pt) 2005-10-06 2011-06-28 Sanofi Aventis n-[1,3,4]-tiadiazol-2-il-benzeno sulfonamidas, processos para sua preparação e seu uso como produtos farmacêuticos
DE102005055355A1 (de) 2005-11-21 2007-10-31 Merck Patent Gmbh 3,6-Dihydro-2-oxo-6H-[1,3,4]thiadiazinderivate
JP2009524591A (ja) 2005-12-21 2009-07-02 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネルのモジュレーターとしての複素環誘導体
DK2420494T3 (en) 2006-08-16 2015-01-12 J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Gladstone Use of thiadiazole compounds as inhibitors of kynurenine 3-monooxygenase
WO2008064116A2 (fr) 2006-11-16 2008-05-29 Abbott Laboratories Procédé pour éviter ou traiter les rejets lors de transplantations d'organes, de cellules souches hématopoïétiques ou de moelle osseuse
WO2008063668A1 (fr) 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Inhibiteurs de métalloprotéase hétérobicyclique
US20080194557A1 (en) 2007-01-18 2008-08-14 Joseph Barbosa Methods and compositions for the treatment of pain, inflammation and cancer
US8124610B2 (en) 2007-07-13 2012-02-28 Icagen Inc. Sodium channel inhibitors
EP2215066A1 (fr) 2007-11-01 2010-08-11 Sirtris Pharmaceuticals, Inc. Dérivés d'amide comme modulateurs de sirtuines
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
AU2008340756A1 (en) 2007-12-26 2009-07-02 Sanofi-Aventis Cyclic pyridyl-N-(1,3,4)-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals
WO2010019788A1 (fr) 2008-08-13 2010-02-18 Smed-Ta/Td. Llc Implants d'apport de médicament
WO2010046780A2 (fr) 2008-10-22 2010-04-29 Institut Pasteur Korea Composés antiviraux
JP5731479B2 (ja) 2009-04-21 2015-06-10 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ Ｈｓｐ９０阻害剤としてのレゾルシノール誘導体
UA107360C2 (en) 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
JP5225470B2 (ja) 2009-08-07 2013-07-03 中外製薬株式会社 アミノピラゾール誘導体
US20130022629A1 (en) 2010-01-04 2013-01-24 Sharpe Arlene H Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
CN101845043A (zh) 2010-01-15 2010-09-29 江苏省农药研究所股份有限公司 邻杂环甲酰苯胺类化合物及其合成方法和应用
WO2011085575A1 (fr) 2010-01-15 2011-07-21 江苏省农药研究所股份有限公司 Composés de formanilide hétérocyclique, leurs procédés de synthèse et leur utilisation
CN101747325A (zh) 2010-01-15 2010-06-23 江苏省农药研究所股份有限公司 邻杂环甲酰苯胺类化合物及其合成方法和应用
EP2563761A1 (fr) 2010-04-29 2013-03-06 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Activateurs de la pyruvate kinase humaine
TW201210597A (en) 2010-06-09 2012-03-16 Gilead Sciences Inc Inhibitors of hepatitis C virus
WO2012007868A2 (fr) 2010-07-12 2012-01-19 Pfizer Limited Composés chimiques
CA2818903C (fr) 2010-12-14 2021-03-23 Electrophoretics Limited 5-(1,3-benzoxazol-2-yl)-4-(pyridine-4-yl)pyrimidine-2-amine et son utilisation comme inhibiteur de caseine kinase 1 delta
US8987271B2 (en) 2010-12-22 2015-03-24 Eutropics Pharmaceuticals, Inc. 2,2′-biphenazine compounds and methods useful for treating disease
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
PL220630B1 (pl) 2012-12-28 2015-11-30 Inst Immunologii I Terapii Doświadczalnej Pan Nowe sulfonamidowe pochodne izoksazolo[5,4-b]pirydyny o aktywności przeciwbakteryjnej, sposób ich wytwarzania oraz nowe zastosowanie 3-aminoizoksazolo[5,4-b]pirydyny
MX2015010775A (es) * 2013-03-15 2016-04-25 Genentech Inc Benzoxazoles sustituidos y metodos para usarlos.
WO2015102929A1 (fr) 2013-12-30 2015-07-09 Novartis Ag Dérivés de sulfonamide tricycliques
US10065945B2 (en) 2014-01-24 2018-09-04 Merck Sharp & Dohme Corp. Isoquinoline derivatives as MGAT2 inhibitors
CA2946702C (fr) 2014-04-23 2022-06-28 Mitsubishi Tanabe Pharma Corporation Compose heterocyclique bicycle ou tricycle
JP5900759B2 (ja) 2014-09-25 2016-04-06 Toto株式会社 小便器
EA031895B1 (ru) 2015-02-24 2019-03-29 Пфайзер Инк. Замещенные нуклеозидные производные, полезные в качестве агентов против рака
GB201510019D0 (en) 2015-06-09 2015-07-22 Cancer Therapeutics Crc Pty Ltd Compounds
WO2017002120A1 (fr) 2015-07-02 2017-01-05 Yeda Research And Development Co. Ltd. Inhibiteurs sélectifs de cellules sénescentes et leurs utilisations
WO2017098421A1 (fr) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Composés benzothiadiazine
CN107098846B (zh) * 2016-02-26 2020-10-09 中国医学科学院药物研究所 N-酰基磺酰胺类FBPase抑制剂、其制备方法、药物组合物及用途
JP2019533022A (ja) 2016-10-24 2019-11-14 ユマニティ セラピューティクス，インコーポレーテッド 化合物及びその使用
WO2018102419A1 (fr) 2016-11-29 2018-06-07 Epizyme, Inc. Composés contenant un groupe sulfonique en tant qu'inhibiteurs de kat
WO2018226976A1 (fr) 2017-06-08 2018-12-13 Kura Oncology, Inc. Procédés et compositions d'inhibition de l'interaction de la ménine avec les protéines mll
GB201810092D0 (en) * 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
RS64931B9 (sr) 2019-06-18 2025-06-30 Pfizer Derivati benzizoxazol sulfonamida

Also Published As

Publication number Publication date
MD3986890T3 (ro) 2025-07-31
PE20220808A1 (es) 2022-05-20
DK3986890T3 (da) 2023-12-18
KR102823056B1 (ko) 2025-06-23
TWI787620B (zh) 2022-12-21
EP3986890B9 (fr) 2025-04-16
ECSP21091615A (es) 2022-01-31
LT4299135T (lt) 2025-09-10
IL288802B1 (en) 2025-04-01
HRP20231501T1 (hr) 2024-03-01
JP2022537285A (ja) 2022-08-25
DK4299135T3 (da) 2025-09-08
EP4299135B1 (fr) 2025-08-06
JP7352662B2 (ja) 2023-09-28
CR20210627A (es) 2022-02-08
PT4299135T (pt) 2025-10-09
WO2020254946A1 (fr) 2020-12-24
UA129891C2 (uk) 2025-09-03
PL4299135T3 (pl) 2025-11-12
RS64931B1 (sr) 2023-12-29
MX2021016085A (es) 2022-04-20
CN114364672A (zh) 2022-04-15
IL288802B2 (en) 2025-08-01
IL288802A (en) 2022-02-01
ES3043899T3 (en) 2025-11-26
US11492346B2 (en) 2022-11-08
UY38752A (es) 2021-01-29
AU2020296361A1 (en) 2022-01-06
BR112021025528A2 (pt) 2022-04-19
CA3143666A1 (fr) 2020-12-24
AU2023274178A1 (en) 2024-02-15
LT3986890T (lt) 2023-12-11
CL2021003372A1 (es) 2022-10-07
MD3986890T2 (ro) 2024-04-30
JP2023175821A (ja) 2023-12-12
RS67276B1 (sr) 2025-10-31
MD4299135T2 (ro) 2025-11-30
MY210207A (en) 2025-09-03
RS64931B9 (sr) 2025-06-30
PT3986890T (pt) 2024-01-17
EP4299135A3 (fr) 2024-02-28
PL3986890T3 (pl) 2024-03-11
EP4299135A2 (fr) 2024-01-03
KR20220024671A (ko) 2022-03-03
HUE064683T2 (hu) 2024-04-28
FI4299135T3 (fi) 2025-10-01
SI4299135T1 (sl) 2025-12-31
EP3986890A1 (fr) 2022-04-27
ES2969616T3 (es) 2024-05-21
US20200399258A1 (en) 2020-12-24
CA3143666C (fr) 2024-06-11
CO2021017504A2 (es) 2022-01-17
FI3986890T3 (fi) 2024-01-15
TW202115048A (zh) 2021-04-16
US12371425B2 (en) 2025-07-29
CN114364672B (zh) 2024-09-06
US20230174522A1 (en) 2023-06-08
HRP20251225T1 (hr) 2025-12-05
SI3986890T1 (sl) 2024-03-29
PH12021553107A1 (en) 2022-08-01
EP3986890B1 (fr) 2023-11-15

Similar Documents

Publication Publication Date Title
MA67365B1 (fr) Dérivés de benzisoxazole sulfonamide
TN2009000544A1 (fr) Derives de benzimidazole
MA30403B1 (fr) Derives d&#39;acides cycloalkylamines et leurs compositions pharmaceutiques
MA54327B1 (fr) Inhibiteurs de kras g12c
MA56883B1 (fr) Dérivés de 2-hydroxycycloalcane-1-carbamoyle
MA58498B1 (fr) Agonistes hétérocycliques de glp-1
TN2014000115A1 (fr) Derives de pyrrolopyrimidines et de purines
MA55890B1 (fr) Modulateurs de thr-beta avec un groupe de tête dioxo-1,2,4-triazyl
TNSN08270A1 (fr) Dérivés pyrimidiques destinés à traiter une croissance cellulaire anormale
MA52360B1 (fr) Dérivés de 2-amino-pyridine ou de 2-amino-pyrimidine utilisés en tant qu&#39;inhibiteurs de kinases dépendantes des cyclines
MA28747B1 (fr) Dérivés de pyridine
MA31419B1 (fr) Derives de pyridine
MA29926B1 (fr) Derives de pyrazine
TN2009000428A1 (fr) Derives de sulfonylamides destines au traitement d&#39;une croissance cellulaire anormale
MA30344B1 (fr) Pyrazoles actifs sur la 11-beta-hsd-1
MA30142B1 (fr) Agonistes du recepteur de neuropeptide-2
RU2342367C2 (ru) Ненуклеозидные ингибиторы i обратной транскриптазы, предназначенные для лечения заболеваний, опосредованных вич
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
MA31754B1 (fr) Cis-imidazolines chirales
MA27560A1 (fr) Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation
MA31894B1 (fr) Composes organiques
MA39043A1 (fr) Dérivés de purine substitués en positions 2 et 6, et leur utilisation dans le traitement des désordres prolifératifs
MA31761B1 (fr) Nouveaux inhibiteurs de seh et leur utilisation
TR200003383T2 (tr) HIV ve diğer virüs enfeksiyonlarının tedavisine yönelik bileşimler.
MA57000B1 (fr) Dérivés d&#39;alpha-d-galactopyranoside